FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Composition",
  "id": "399874",
  "meta": {
    "versionId": "5",
    "lastUpdated": "2025-12-11T20:35:21.032Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"
    ]
  },
  "language": "en",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "contained": [
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-AllCauseMortality",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "All-cause mortality (timeframe for NCT03421379)",
      "status": "active",
      "definition": {
        "concept": {
          "text": "All-cause mortality"
        }
      },
      "handling": "boolean",
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-SeriousAdverseEvents",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Serious Adverse Events (timeframe for NCT03421379)",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Serious Adverse Events"
        }
      },
      "handling": "boolean",
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvents",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Other Adverse Events (timeframe for NCT03421379)",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Other Adverse Events"
        }
      },
      "handling": "boolean",
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-AllCauseMortality-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_AllCauseMortality_EG000",
      "title": "All-cause mortality for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-AllCauseMortality",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-SeriousAdverseEvents-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_SeriousAdverseEvents_EG000",
      "title": "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-SeriousAdverseEvents",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvents-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvents_EG000",
      "title": "Other Adverse Events for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvents",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.2113
          },
          "numberAffected": 15,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-AllCauseMortality-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_AllCauseMortality_EG001",
      "title": "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-AllCauseMortality",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-SeriousAdverseEvents-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_SeriousAdverseEvents_EG001",
      "title": "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-SeriousAdverseEvents",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvents-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvents_EG001",
      "title": "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvents",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.1857
          },
          "numberAffected": 13,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-SeriousAdverseEvent-0-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_SeriousAdverseEvent_0_EG000",
      "title": "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-SeriousAdverseEvent-0",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-SeriousAdverseEvent-0-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_SeriousAdverseEvent_0_EG001",
      "title": "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-SeriousAdverseEvent-0",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-SeriousAdverseEvent-0",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Vertigo positional as serious adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Vertigo positional as serious adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Serious Adverse Event"
        },
        {
          "text": "Ear and labyrinth disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-0-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_0_EG000",
      "title": "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-0",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0282
          },
          "numberOfEvents": 2,
          "numberAffected": 2,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-0-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_0_EG001",
      "title": "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-0",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-0",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Ear pain as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Ear pain as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Ear and labyrinth disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-1-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_1_EG000",
      "title": "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-1",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-1-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_1_EG001",
      "title": "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-1",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-1",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Eye pain as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Eye pain as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Eye disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-2-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_2_EG000",
      "title": "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-2",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-2-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_2_EG001",
      "title": "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-2",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-2",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Eye pruritus as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Eye pruritus as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Eye disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-3-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_3_EG000",
      "title": "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-3",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-3-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_3_EG001",
      "title": "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-3",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-3",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Lacrimation increased as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Lacrimation increased as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Eye disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-4-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_4_EG000",
      "title": "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-4",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-4-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_4_EG001",
      "title": "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-4",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-4",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Diarrhoea as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Diarrhoea as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Gastrointestinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-5-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_5_EG000",
      "title": "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-5",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0704
          },
          "numberOfEvents": 5,
          "numberAffected": 5,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-5-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_5_EG001",
      "title": "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-5",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.1571
          },
          "numberOfEvents": 11,
          "numberAffected": 11,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-5",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Nausea as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Nausea as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Gastrointestinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-6-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_6_EG000",
      "title": "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-6",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-6-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_6_EG001",
      "title": "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-6",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-6",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Toothache as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Toothache as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Gastrointestinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-7-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_7_EG000",
      "title": "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-7",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0282
          },
          "numberOfEvents": 2,
          "numberAffected": 2,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-7-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_7_EG001",
      "title": "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-7",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0571
          },
          "numberOfEvents": 5,
          "numberAffected": 4,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-7",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Vomiting as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Vomiting as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Gastrointestinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-8-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_8_EG000",
      "title": "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-8",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-8-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_8_EG001",
      "title": "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-8",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-8",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Feeling abnormal as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Feeling abnormal as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "General disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-9-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_9_EG000",
      "title": "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-9",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-9-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_9_EG001",
      "title": "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-9",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-9",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Cystitis as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Cystitis as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Infections and infestations"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-10-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_10_EG000",
      "title": "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-10",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-10-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_10_EG001",
      "title": "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-10",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0286
          },
          "numberOfEvents": 2,
          "numberAffected": 2,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-10",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Blood pressure decreased as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Blood pressure decreased as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Investigations"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-11-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_11_EG000",
      "title": "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-11",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0563
          },
          "numberOfEvents": 4,
          "numberAffected": 4,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-11-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_11_EG001",
      "title": "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-11",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-11",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Blood pressure increased as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Blood pressure increased as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Investigations"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-12-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_12_EG000",
      "title": "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-12",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-12-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_12_EG001",
      "title": "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-12",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-12",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Back pain as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Back pain as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Musculoskeletal and connective tissue disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-13-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_13_EG000",
      "title": "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-13",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-13-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_13_EG001",
      "title": "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-13",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-13",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Headache as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Headache as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Nervous system disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-14-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_14_EG000",
      "title": "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-14",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-14-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_14_EG001",
      "title": "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-14",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-14",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Nasal congestion as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Nasal congestion as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-15-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_15_EG000",
      "title": "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-15",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-15-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_15_EG001",
      "title": "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-15",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-15",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Nasal pruritus as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Nasal pruritus as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-16-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_16_EG000",
      "title": "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-16",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0141
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-16-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_16_EG001",
      "title": "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-16",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-16",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Oropharyngeal pain as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Oropharyngeal pain as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-17-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_17_EG000",
      "title": "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-17",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0845
          },
          "numberOfEvents": 6,
          "numberAffected": 6,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-17-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_17_EG001",
      "title": "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-17",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-17",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Rhinalgia as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Rhinalgia as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-18-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_18_EG000",
      "title": "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-18",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-18-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_18_EG001",
      "title": "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-18",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-18",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Cold sweat as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Cold sweat as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Skin and subcutaneous tissue disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-19-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_19_EG000",
      "title": "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-19",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-19-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_19_EG001",
      "title": "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-19",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-19",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Hot flush as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Hot flush as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Vascular disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-20-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_20_EG000",
      "title": "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-20",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-20-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_20_EG001",
      "title": "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-20",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-20",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Hypertension as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Hypertension as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Vascular disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-21-EG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_21_EG000",
      "title": "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Nasal Powder",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-21",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0
          },
          "numberOfEvents": 0,
          "numberAffected": 0,
          "sampleSize": {
            "knownDataCount": 71
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-OtherAdverseEvent-21-EG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name": "NCT03421379_OtherAdverseEvent_21_EG001",
      "title": "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status": "active",
      "variableDefinition": [
        {
          "description": "Glucagon Hydrochloride Solution",
          "variableRole": "population",
          "observed": {
            "display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note": [
            {
              "text": "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole": "outcome",
          "observed": {
            "reference": "#NCT03421379-OtherAdverseEvent-21",
            "type": "EvidenceVariable"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "text": "Percentage"
          },
          "quantity": {
            "value": 0.0143
          },
          "numberOfEvents": 1,
          "numberAffected": 1,
          "sampleSize": {
            "knownDataCount": 70
          }
        }
      ]
    },
    {
      "resourceType": "EvidenceVariable",
      "id": "NCT03421379-OtherAdverseEvent-21",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title": "Peripheral coldness as other adverse event",
      "status": "active",
      "definition": {
        "concept": {
          "text": "Peripheral coldness as other adverse event"
        }
      },
      "definitionModifier": [
        {
          "code": {
            "text": "Adverse event assessment type"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/definition-method",
                "code": "systematic-assessment",
                "display": "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code": {
            "text": "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept": {
            "text": "MedDRA 18.1"
          }
        }
      ],
      "handling": "boolean",
      "classifier": [
        {
          "text": "Other Adverse Event"
        },
        {
          "text": "Vascular disorders"
        }
      ],
      "timing": {
        "text": "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    }
  ],
  "url": "https://fevir.net/resources/Composition/399874",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "399874",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "FEvIR Linking Identifier"
      },
      "system": "https://fevir.net/FLI",
      "value": "NCT03421379-adverse-events-report",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "status": "final",
  "type": {
    "coding": [
      {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "OutcomeMeasureReport",
        "display": "OutcomeMeasureReport"
      }
    ],
    "text": "Outcome Measure Report"
  },
  "date": "2025-12-11T20:35:21.032Z",
  "author": [
    {
      "display": "[No author listed.]"
    }
  ],
  "title": "Adverse Events Report for NCT03421379",
  "custodian": {
    "reference": "Organization/118079",
    "type": "Organization",
    "display": "Computable Publishing LLC"
  },
  "relatesTo": [
    {
      "type": "cite-as",
      "targetMarkdown": "Adverse Events Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399874. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399874. Computable resource at: https://fevir.net/resources/Composition/399874#json."
    }
  ],
  "section": [
    {
      "title": "Events Frequency Threshold",
      "code": {
        "text": "EventsFrequencyThreshold"
      },
      "text": {
        "status": "generated",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">0%</div>"
      }
    },
    {
      "title": "Events Time Frame",
      "code": {
        "text": "EventsTimeFrame"
      },
      "text": {
        "status": "generated",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">From Baseline to End of Follow-up (Up to 2 Months)</div>"
      }
    },
    {
      "title": "Events Description",
      "code": {
        "text": "EventsDescription"
      },
      "text": {
        "status": "generated",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug.</div>"
      }
    },
    {
      "title": "Glucagon Nasal Powder",
      "code": {
        "text": "EG000 Glucagon Nasal Powder"
      },
      "section": [
        {
          "title": "Event Group Description",
          "code": {
            "text": "EventGroupDescription"
          },
          "text": {
            "status": "generated",
            "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
          }
        }
      ]
    },
    {
      "title": "Glucagon Hydrochloride Solution",
      "code": {
        "text": "EG001 Glucagon Hydrochloride Solution"
      },
      "section": [
        {
          "title": "Event Group Description",
          "code": {
            "text": "EventGroupDescription"
          },
          "text": {
            "status": "generated",
            "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
          }
        }
      ]
    },
    {
      "title": "Total Mortality",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Total Mortality"
      },
      "focus": {
        "reference": "#NCT03421379-AllCauseMortality",
        "type": "EvidenceVariable",
        "display": "All-cause mortality (timeframe for NCT03421379)"
      },
      "entry": [
        {
          "reference": "#NCT03421379-AllCauseMortality-EG000",
          "type": "Evidence",
          "display": "All-cause mortality for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference": "#NCT03421379-AllCauseMortality-EG001",
          "type": "Evidence",
          "display": "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379"
        }
      ]
    },
    {
      "title": "Total Serious Events",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Total Serious Events"
      },
      "focus": {
        "reference": "#NCT03421379-SeriousAdverseEvents",
        "type": "EvidenceVariable",
        "display": "Serious Adverse Events (timeframe for NCT03421379)"
      },
      "entry": [
        {
          "reference": "#NCT03421379-SeriousAdverseEvents-EG000",
          "type": "Evidence",
          "display": "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference": "#NCT03421379-SeriousAdverseEvents-EG001",
          "type": "Evidence",
          "display": "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379"
        }
      ]
    },
    {
      "title": "Total Other Events",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Total Other Events"
      },
      "focus": {
        "reference": "#NCT03421379-OtherAdverseEvents",
        "type": "EvidenceVariable",
        "display": "Other Adverse Events (timeframe for NCT03421379)"
      },
      "entry": [
        {
          "reference": "#NCT03421379-OtherAdverseEvents-EG000",
          "type": "Evidence",
          "display": "Other Adverse Events for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference": "#NCT03421379-OtherAdverseEvents-EG001",
          "type": "Evidence",
          "display": "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379"
        }
      ]
    },
    {
      "title": "Serious Event List",
      "code": {
        "text": "SeriousEventList"
      },
      "section": [
        {
          "title": "Vertigo positional",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-SeriousAdverseEvent-0",
            "type": "EvidenceVariable",
            "display": "Vertigo positional as serious adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-SeriousAdverseEvent-0-EG000",
              "type": "Evidence",
              "display": "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-SeriousAdverseEvent-0-EG001",
              "type": "Evidence",
              "display": "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        }
      ]
    },
    {
      "title": "Other Event List",
      "code": {
        "text": "OtherEventList"
      },
      "section": [
        {
          "title": "Ear pain",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-0",
            "type": "EvidenceVariable",
            "display": "Ear pain as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-0-EG000",
              "type": "Evidence",
              "display": "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-0-EG001",
              "type": "Evidence",
              "display": "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Eye pain",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-1",
            "type": "EvidenceVariable",
            "display": "Eye pain as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-1-EG000",
              "type": "Evidence",
              "display": "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-1-EG001",
              "type": "Evidence",
              "display": "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Eye pruritus",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-2",
            "type": "EvidenceVariable",
            "display": "Eye pruritus as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-2-EG000",
              "type": "Evidence",
              "display": "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-2-EG001",
              "type": "Evidence",
              "display": "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Lacrimation increased",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-3",
            "type": "EvidenceVariable",
            "display": "Lacrimation increased as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-3-EG000",
              "type": "Evidence",
              "display": "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-3-EG001",
              "type": "Evidence",
              "display": "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Diarrhoea",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-4",
            "type": "EvidenceVariable",
            "display": "Diarrhoea as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-4-EG000",
              "type": "Evidence",
              "display": "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-4-EG001",
              "type": "Evidence",
              "display": "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Nausea",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-5",
            "type": "EvidenceVariable",
            "display": "Nausea as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-5-EG000",
              "type": "Evidence",
              "display": "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-5-EG001",
              "type": "Evidence",
              "display": "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Toothache",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-6",
            "type": "EvidenceVariable",
            "display": "Toothache as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-6-EG000",
              "type": "Evidence",
              "display": "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-6-EG001",
              "type": "Evidence",
              "display": "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Vomiting",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-7",
            "type": "EvidenceVariable",
            "display": "Vomiting as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-7-EG000",
              "type": "Evidence",
              "display": "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-7-EG001",
              "type": "Evidence",
              "display": "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Feeling abnormal",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-8",
            "type": "EvidenceVariable",
            "display": "Feeling abnormal as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-8-EG000",
              "type": "Evidence",
              "display": "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-8-EG001",
              "type": "Evidence",
              "display": "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Cystitis",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-9",
            "type": "EvidenceVariable",
            "display": "Cystitis as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-9-EG000",
              "type": "Evidence",
              "display": "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-9-EG001",
              "type": "Evidence",
              "display": "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Blood pressure decreased",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-10",
            "type": "EvidenceVariable",
            "display": "Blood pressure decreased as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-10-EG000",
              "type": "Evidence",
              "display": "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-10-EG001",
              "type": "Evidence",
              "display": "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Blood pressure increased",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-11",
            "type": "EvidenceVariable",
            "display": "Blood pressure increased as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-11-EG000",
              "type": "Evidence",
              "display": "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-11-EG001",
              "type": "Evidence",
              "display": "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Back pain",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-12",
            "type": "EvidenceVariable",
            "display": "Back pain as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-12-EG000",
              "type": "Evidence",
              "display": "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-12-EG001",
              "type": "Evidence",
              "display": "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Headache",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-13",
            "type": "EvidenceVariable",
            "display": "Headache as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-13-EG000",
              "type": "Evidence",
              "display": "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-13-EG001",
              "type": "Evidence",
              "display": "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Nasal congestion",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-14",
            "type": "EvidenceVariable",
            "display": "Nasal congestion as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-14-EG000",
              "type": "Evidence",
              "display": "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-14-EG001",
              "type": "Evidence",
              "display": "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Nasal pruritus",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-15",
            "type": "EvidenceVariable",
            "display": "Nasal pruritus as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-15-EG000",
              "type": "Evidence",
              "display": "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-15-EG001",
              "type": "Evidence",
              "display": "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Oropharyngeal pain",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-16",
            "type": "EvidenceVariable",
            "display": "Oropharyngeal pain as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-16-EG000",
              "type": "Evidence",
              "display": "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-16-EG001",
              "type": "Evidence",
              "display": "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Rhinalgia",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-17",
            "type": "EvidenceVariable",
            "display": "Rhinalgia as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-17-EG000",
              "type": "Evidence",
              "display": "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-17-EG001",
              "type": "Evidence",
              "display": "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Cold sweat",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-18",
            "type": "EvidenceVariable",
            "display": "Cold sweat as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-18-EG000",
              "type": "Evidence",
              "display": "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-18-EG001",
              "type": "Evidence",
              "display": "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Hot flush",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-19",
            "type": "EvidenceVariable",
            "display": "Hot flush as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-19-EG000",
              "type": "Evidence",
              "display": "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-19-EG001",
              "type": "Evidence",
              "display": "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Hypertension",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-20",
            "type": "EvidenceVariable",
            "display": "Hypertension as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-20-EG000",
              "type": "Evidence",
              "display": "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-20-EG001",
              "type": "Evidence",
              "display": "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title": "Peripheral coldness",
          "code": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "results",
                "display": "Results"
              }
            ]
          },
          "focus": {
            "reference": "#NCT03421379-OtherAdverseEvent-21",
            "type": "EvidenceVariable",
            "display": "Peripheral coldness as other adverse event"
          },
          "entry": [
            {
              "reference": "#NCT03421379-OtherAdverseEvent-21-EG000",
              "type": "Evidence",
              "display": "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference": "#NCT03421379-OtherAdverseEvent-21-EG001",
              "type": "Evidence",
              "display": "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        }
      ]
    }
  ]
}